Satsuma Pharmaceuticals Announces FDA Acceptance Of 505(b)(2) NDA For STS101, A Novel And Investigational Dihydroergotamine Nasal Powder Product For The Acute Treatment Of Migraine
Portfolio Pulse from Happy Mohamed
Satsuma Pharmaceuticals' 505(b)(2) NDA for STS101, a novel migraine treatment, has been accepted for review by the FDA. Satsuma is in the process of being acquired by Shin Nippon Biomedical Laboratories, with a tender offer expiring on June 5, 2023.
May 18, 2023 | 8:03 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Satsuma Pharmaceuticals' NDA for STS101 has been accepted by the FDA, potentially boosting the company's value as it is being acquired by Shin Nippon Biomedical Laboratories.
The FDA's acceptance of Satsuma's NDA for STS101 is a positive development for the company, as it indicates progress towards potential approval of the migraine treatment. This news could positively impact Satsuma's stock price in the short term, especially as the company is in the process of being acquired by Shin Nippon Biomedical Laboratories.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100